Recruiting

Testing a gut bacteria treatment for active ulcerative colitis

Plain-English translation of NCT07401680 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Ulcerative Colitis research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing LFMT (a capsule form of processed gut bacteria) to see if it can help control active ulcerative colitis symptoms. You would either add the medication to your current treatment or start it alongside a new advanced ulcerative colitis drug. The study will compare the medication to placebo (identical-looking capsules with no active ingredient) to see which works better.

Ulcerative colitis happens when the gut lining becomes inflamed and damaged, causing pain and other symptoms. Researchers believe that this medication—which contains beneficial bacteria that normally live in a healthy gut—might help calm the inflammation and improve symptoms in people whose current treatments aren't working well enough.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with ulcerative colitis confirmed by scope and biopsy
you currently have active ulcerative colitis symptoms
you are willing to take capsules daily and follow all study procedures
you are able to use effective birth control (if you can become pregnant) for at least 4 weeks before and during the trial

You likely don't qualify if…

you have severe ulcerative colitis requiring hospitalization
you have taken antibiotics in the 30 days before enrolling or expect to need them during the study
you have taken probiotics (other than dietary sources) or received this type of treatment in the past 6 months
you are pregnant, breastfeeding, or unwilling to use birth control
you have had abdominal surgery in the past 60 days or have a planned surgery during the study

What participation looks like

You would visit one of three Canadian healthcare centers and take capsules daily for about 6 months total. The first 8 weeks involve a higher starting dose that gradually decreases, followed by a lower maintenance dose for 16 weeks. You'll either receive the active medication or placebo (you won't know which), and either way, you'll either keep taking your current treatment or start a new advanced medication alongside the study capsules. The research team will monitor your symptoms and health throughout.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(2 sites)

Canada

University of Calgary, Calgary, Alberta

University of Alberta, Edmonton, Alberta